[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.205.150.215. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Editorial
November 2015

Are the Current Risks of Asymptomatic Carotid Stenosis Exaggerated?Further Evidence Supporting the CREST 2 Trial

Author Affiliations
  • 1Department of Neurology, University of Miami Miller School of Medicine, Miami, Florida
  • 2Miami Veterans Affairs Hospital, Miami, Florida
JAMA Neurol. 2015;72(11):1233-1234. doi:10.1001/jamaneurol.2015.2196

In the past 2 decades, 2 large multicenter trials have demonstrated the efficacy of carotid endarterectomy (CEA) for patients with asymptomatic carotid stenosis: the Asymptomatic Carotid Atherosclerosis Study (ACAS) and the Asymptomatic Carotid Surgery Trial (ACST).1,2 These trials found that CEA, compared with best medical therapy, was associated with a significant relative risk reduction of 50% during 5 years but only an absolute reduction in ipsilateral stroke of 0.5% to 1% per year. With the number needed to treat to prevent 1 stroke in 1 year approaching 100 to 200, whether this degree of stroke reduction is clinically significant has been debated.3 The trials have led to evidence-based recommendations supporting CEA for selected patients with asymptomatic carotid stenosis and a surge in carotid revascularization procedures in recent years. Among Medicare patients in the period 2004-2006, 87% of carotid artery stenting (CAS) and 88% of CEA procedures were performed in asymptomatic patients.4

First Page Preview View Large
First page PDF preview
First page PDF preview
×